{
    "id": 32729,
    "fullName": "CD38 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CD38 over exp indicates an over expression of the Cd38 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 952,
        "geneSymbol": "CD38",
        "terms": [
            "CD38",
            "ADPRC 1",
            "ADPRC1"
        ]
    },
    "variant": "over exp",
    "createDate": "03/10/2020",
    "updateDate": "03/10/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20822,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-169 treatment induced cytotoxicity against multiple myeloma cell lines overexpressing CD38 in culture, and induced regression in a cell line xenograft model (Cancer Res 2019;79(13 Suppl):Abstract nr 2384).",
            "molecularProfile": {
                "id": 35359,
                "profileName": "CD38 over exp"
            },
            "therapy": {
                "id": 9488,
                "therapyName": "TAK-169",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18081,
                    "pubMedId": null,
                    "title": "TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2384"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35359,
            "profileName": "CD38 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}